_managing-mouth-sores-from-everolimus-in-breast-cancer-preview-1.jpg "Managing Mouth Sores from Everolimus in Breast Cancer from everolimus chemotherapy Video Screenshot Preview 1")
Gallery_managing-mouth-sores-from-everolimus-in-breast-cancer-preview-3.jpg "Managing Mouth Sores from Everolimus in Breast Cancer from everolimus chemotherapy Video Screenshot Preview 3")
Gallery_managing-mouth-sores-from-everolimus-in-breast-cancer-preview-hqdefault.jpg "Managing Mouth Sores from Everolimus in Breast Cancer from everolimus chemotherapy Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 5 minutes 1 second
👁 View: 1K times
Play Audio:👁 View: 1K times
Description:
OncLiveTV
OncLiveTV
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_cora-n-sternberg-md-on-renal-and-bladder-cancers-focus-on-immunotherapy.webp "Cora N. Sternberg, MD, of San Camillo-Forlanini Hospital and the Israel Englander Institute of Precision Medicine at Weill Cornell, discusses results from the phase III CheckMate-025 study on nivolumab vs everolimus for mRCC; the CheckMate-214 study on nivolumab, ipilimumab, and sunitinib for treatment-naive advanced or metastatic clear-cell RCC; and immunotherapy for urothelial cancer for both first- line cisplatin-ineligible and second-line therapy after cisplatin chemotherapy.")
⏲ 1 min 92 sec ✓ 21-Oct-2018
_winship-grand-rounds-august-4-2021-jonathan-strosberg-md.webp "Winship Cancer Institute of Emory University")
_managing-the-toxicity-of-everolimus-in-breast-cancer.webp "OncLiveTV")
_92.webp "A self-confessed \")
_managing-mouth-sores-from-everolimus-in-breast-cancer.webp "OncLiveTV")
_recent-advances-in-advanced-breast-cancer.webp "Prof Stephen Johnston – Royal Marsden Hospital, UK; Adjunct Prof Johanna Mattson - Helsinki University Central Hospital, Finland; Prof Ahmad Awada, Jules Bordet Institute, Belgium; Prof Rob Coleman - Weston Park Hospital, UK:nnnThe BOLERO (Breast Cancer Trials of Oral Everolimus) clinical trial is a study which assessed the use of the mTOR inhibitor everolimus in combination with exemestane as way to overcome endocrine resistance in breast cancer patients. Early results of this trial have show")
_integration-of-radiotherapy-in-muscle-invasive-bladder-cancer.webp "UBC Urology Rounds")
_winship-grand-rounds-july-19-2017-mehmet-asim-bilen-md.webp "Winship Cancer Institute of Emory University")
_cora-n-sternberg-md-on-renal-and-bladder-cancers-focus-on-immunotherapy.jpg)
_winship-grand-rounds-august-4-2021-jonathan-strosberg-md.jpg)
_managing-the-toxicity-of-everolimus-in-breast-cancer.jpg)
_92.jpg)
_managing-mouth-sores-from-everolimus-in-breast-cancer.jpg)
_recent-advances-in-advanced-breast-cancer.jpg)
_integration-of-radiotherapy-in-muscle-invasive-bladder-cancer.jpg)
_winship-grand-rounds-july-19-2017-mehmet-asim-bilen-md.jpg)
![[+]](/images/menu.gif){kind=small}